MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02908nam a22004817a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
180619s20192019 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1078-1552 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.1177/1078155218774895 [doi] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
29768958 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab. |
| 251 ## - Source |
|---|
| Source |
Journal of Oncology Pharmacy Practice. 25(4):1011-1015, 2019 Jun. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
J Oncol Pharm Pract. 25(4):1011-1015, 2019 Jun. |
| 253 ## - Journal Name |
|---|
| Journal name |
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2019 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2019 |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2018-06-19 |
| 269 ## - Original dates |
|---|
| Original fiscal year |
FY2018 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody used for the management of various solid malignancies including colorectal, lung, brain, renal, and ovarian cancers as well as age-related macular degeneration of the eye. It is a vascular endothelial growth factor inhibitor which exhibits its action by blocking the growth of blood vessels in cancerous tissue. Common side effects include hypertension, fatigue, headaches, and increased risk of infections. Atypical hemolytic uremic syndrome is a serious side effect associated with bevacizumab due to its anti-angiogenic effect. It encompasses the clinical triad of thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure, without any association with Shiga toxins. Eculizumab is a terminal complement inhibitor used in the treatment of atypical hemolytic uremic syndrome. Herein, we present three cases of bevacizumab-induced atypical hemolytic syndrome treated successfully with eculizumab. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Antibodies, Monoclonal, Humanized/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Antineoplastic Agents, Immunological/ae [Adverse Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Atypical Hemolytic Uremic Syndrome/ci [Chemically Induced] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Atypical Hemolytic Uremic Syndrome/dt [Drug Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Bevacizumab/ae [Adverse Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Vascular Endothelial Growth Factor A/ai [Antagonists & Inhibitors] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Female |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Middle Aged |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Washington Hospital Center |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
Washington Cancer Institute |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Medicine/General Internal Medicine |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Alhaj-Moustafa, Muhamad |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Fitzpatrick, Kelly |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Pilla, Ravi |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Vakiti, Anusha |
| 790 ## - Authors |
|---|
| All authors |
Alhaj-Moustafa M, Fitzpatrick KW, Pilla R, Singh D, Vakiti A |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1177/1078155218774895">https://dx.doi.org/10.1177/1078155218774895</a> |
| Public note |
https://dx.doi.org/10.1177/1078155218774895 |
| 858 ## - ORCID |
|---|
| ORCID text |
Alhaj-Moustafa, Muhamad |
| Orcid |
<a href="http://orcid.org/0000-0001-8582-1219">http://orcid.org/0000-0001-8582-1219</a> |
| Name |
http://orcid.org/0000-0001-8582-1219 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
